Abstract
This study aimed to assess hepatitis B virus (HBV) reactivation, its impact on prognosis, and its management in patients with HBV-related hepatocellular carcinoma (HCC), who received hepatic arterial infusion chemotherapy (HAIC) plus tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and entecavir (HAIC+TKIs+ICIs+entecavir) treatments. Three hundred and seven patients in five centers with advanced HBV-related HCC, who received the quadruple treatment, were included. The HBV reactivation was observed in 44 (14.3%) patients. HBV-DNA level >= 1 x 10(4) IU/mL, positive HBeAg, and white blood cell count <4 x 10(9)/L were the independent risk factors of HBV reactivation. The median progression-free survival and median overall survival of patients in the HBV non-reactivation group were significantly longer than those of patients in the HBV reactivation group (p < 0.001, p < 0.001). The additional treatment with tenofovir alafenamide fumarate can effectively manage the HBV reactivation and improve the survival of these HBV reactivated HCC patients.
| Original language | English |
|---|---|
| Article number | 112689 |
| Number of pages | 11 |
| Journal | ISCIENCE |
| Volume | 28 |
| Issue number | 6 |
| Early online date | May 2025 |
| DOIs | |
| State | Published - 20 Jun 2025 |
Funding
This study was supported by the grants of National Natural Science Foundation of China (nos. 82372069 and 82072041) , and the Outstanding Youth Foundation of Hubei Province, China (2023AFA107) .
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Health sciences
- Virology
Indexed by
- SCIE
- Scopus
Fingerprint
Dive into the research topics of 'HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver